MYL12A in droplets may be used as a protective molecular marker for ARDS by maintaining neutrophil migration and functional balance: its elevated content is not only associated with the improvement of oxygenation function, but also significantly associated with the reduction of disease severity, providing a potential target for clinical prognosis evaluation and precision immune intervention. Here, MYL12A is linked to acute respiratory distress syndrome.